Politecnico di Torino - Corso Duca degli Abruzzi, 24 - 10129 Torino, ITALY

+39 011 090 6100 info@tech-share.it

Therapeutic treatment against neurodegenerative prion diseases

neurodegenerative diseasesParkinson & Alzheimer diseaseprion-like diseasesprotease inhibitorsSerpina3

Introduction

To date, despite numerous active efforts, there are no drugs available for the cure of the neurodegenerative diseases collectively referred as prion and prion-like disorders. Through this breakthrough invention, we are presenting a new class of small molecules acting as SERPINA3 inhibitors, which are able to reduce PrPSc accumulation in prion-infected cell lines, thereby representing a new therapeutic treatment against prion and prion-like diseases.

Technical features

To date, despite numerous active efforts, there are no drugs available for the cure of the neurodegenerative diseases collectively referred as prion and prion-like disorders. Symptomatic treatment is the only available option, including the administration to patients of antipsychotics, such as quetiapine and clonazepam, to treat myoclonus, and of selective serotonin re-uptake inhibitors (SSRIs) to treat depression. Indeed, through this invention, we are presenting a new class of small molecules acting as SERPINA3 inhibitors, which are able to reduce PrPSc accumulation in prion-infected cell lines, thereby representing a new therapeutic treatment against prion and prion-like diseases. The development of specific inhibitors of SERPINA3 with an activity in the nanomolar range is expected. The characterization of structural models of the binding of the small molecules with the protein should allow the identification of novel inhibitors with improved potency.

Possible Applications

  • Prion diseases treatment;
  • Use in pharmaceutical compositions as serpina3 inhibitors;

Advantages

  • Potentially effective therapy for the treatment of prion diseases;
  • Valid alternative to the administration of antipsychotics;
  • It allows the identification of new inhibitors for neurodegenerative diseases;
  • Approved reduction in the concentration of infectious agents;